TJP2

Across TCGA pan-cancer cohorts, TJP2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TJP2 data layer compared with 23 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher TJP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TJP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

GBM, LUAD, and CCRCC are the cancer types where TJP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.189	0.517	.010	16	view →
LUAD	DFS	Quartile	II,III,IV	0.672	0.188	.024	2	view →
CCRCC	OS	Median	III,IV	0.609	1.000	.044	2	view →
LSCC	DFS	Median	III,IV	0.830	0.488	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TJP2–GBM (OS)

Open the GBM breakdown →